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Abstract
Further work on the use of albumin in the intensive care unit is
discussed. The interesting pilot study by Dubois and colleagues
examines the potential benefits for albumin supplementation in the
hypoalbuminaemic critically ill patient. Maintaining the fluid theme,
we discuss recent work on factors influencing post-intensive care
unit blood transfusion as well as another study on erythropoietin.
Finally, a large multicentred trial comparing continuous venovenous
haemofiltration with intermittent haemodialysis is outlined, the
results of which pose more questions than answers.
Men worry over the great number of diseases, while
doctors worry over the scarcity of effective remedies.
Pien Chi’ao, Chinese physician ca. 500 BC
A recurring theme in treating the critically ill, and indeed in all
of medicine, is the search for evidence-based practice. As we
all know, however, application of such principles is somewhat
curtailed by the paucity of data even when considering
aspects of treatment that to the ill-informed would seem
fundamental.
The study by Dubois and colleagues in Critical Care
Medicine addresses a fundamental question: the use of
albumin in the critically ill [1]. One may think this is yet
another study adding to the confusion regarding the use of
albumin when compared with other colloids as resuscitative
fluids. But no, this prospective, randomised controlled study
on 100 patients in a mixed intensive care unit (ICU) setting
crudely examined the effect of albumin on organ function in
hypoalbuminaemic patients. All adult patients with serum
albumin <30 g/l were eligible provided that they had an
expected length of stay >72 hours, a life expectancy
>3 months, needed full active treatment and had not
undergone albumin administration in the previous 24 hours.
Those patients with volume overload were excluded. The
primary endpoint was the effect of albumin administration on
the delta Sequential Organ Failure Assessment score from
day 1 to day 7. Three hundred millilitres of 20% albumin was
given on day 1, followed by 200 ml/day providing the serum
albumin remained below 31 g/l. The control group received
no albumin.
Interestingly, nearly 2,000 consecutive patients were screened
before an adequate cohort was achieved, with almost 50% of
patients not being hypoalbuminaemic on admission or during
admission. The results, in brief, showed a greater change in
Sequential Organ Failure Assessment score between the two
groups: 3.1 ± 1.0 in the albumin group compared with
1.4 ± 1.1 in those patients with no albumin administration [1].
The major effects were seen in the cardiovascular,
neurological and respiratory components of the Sequential
Organ Failure Assessment score. Secondary end points
included a similar mortality, length of stay and diuretic use.
Potential benefits, however, were seen in those patients
receiving albumin; for example, the mean daily caloric intake
was higher and the mean daily volume intake was lower –
both variables associated with improved outcome.
So where does this study lead us in the quest for an evidence
base? We know albumin is ‘safe’ [2] but we do not know
whether its usage confers an additional benefit in our critically
ill patients, and in fairness the authors do not make any
extravagant claims. Dubois and colleagues [1] point out that
this is a pilot study and will hopefully pave the way for further
work that will aid our future decision-making.
Another intravenous treatment that has sparked much
debate over the past few years is that of red blood cell
transfusion. Anaemia is common in the critically ill, with
between 40% and 45% of our patients receiving at least one
red blood cell transfusion [3,4]. A recent prospective study
reported in this journal demonstrated that up to 11% of
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survivors from the ICU required red blood cell transfusion
within 7 days of ICU discharge, in keeping with other studies
[5]. Unsurprisingly, associated factors for the need for
transfusion included the haemoglobin level at discharge,
sepsis and unresolved organ failure.
There are potential negative outcomes associated with
repeated blood transfusion in the critically ill patient, and an
alternative approach is the use of erythropoietin. A recent
study in Critical Care Medicine examined the use of recom-
binant erythropoietin in patients in post-ICU long-term acute
care to assess the impact on the need for transfusion [6]. A
total of 84 patients in two centres were randomised to
treatment or to placebo in a double-blind trial for a period of
12 weeks, or until death/discharge. The transfusion threshold
was a haematocrit level less than 24% together with the
clinician’s discretion. Patient groups were well matched,
including biochemical parameters such as iron stores and
serum creatinine (although the starting haemoglobin level
was higher in the treatment group). The primary end point
was the number of red cell units transfused. At 40 days there
was a significant reduction in the number of units transfused
between the groups (P < 0.006); at 84 days the reduction
was still evident but less marked (P < 0.05), reflecting the
increased use of red cells in the initial study period.
Beyond this it is difficult to draw too much more from the paper
by Silver and colleagues. The authors themselves concede
that there are several flaws in the study. The patient numbers
were small with a relatively short follow-up period, and also the
study was powered for the primary endpoint with 86
participants; however, there were 23 patients who were
withdrawn from the study. Analysis was on an intention-to-treat
basis, but there appears to be a degree of post-hoc analysis in
an attempt to add strength to the conclusions provided;
examining mortality/morbidity, the effect on mechanical
ventilation and the length of stay in hospital revealed no
significant differences between the actively treated and
placebo groups. As clinicians we require robust data that we
can then apply to our daily practice, and it is difficult to take a
message from this study that supports any such change. As
concluded by Silver and colleagues, larger studies are
required to take the investigation of the use of recombinant
erythropoietin forward in this patient population. Clinical
studies with a more robust design are required to investigate
safety, efficacy, and potential economic advantages.
One area of critical care management that continually
provokes debate is the modality of choice for the treatment of
acute renal failure in the setting of the ICU. The study by
Vinsonneau and colleagues appears at first glance to answer
this burning question; but although the title promises much,
one is left a little dissatisfied [7]. This was a large,
prospective, randomised multicentre study in 21 ICUs over a
3.5-year period, and the organisation involved was impres-
sive. The primary end point was the 60-day mortality following
the randomisation of 360 patients to either continuous
venovenous haemodiafiltration or intermittent haemodialysis
(IHD) in centres familiar with both techniques. As with all
studies on acute renal failure, the eligibility criteria suffer from
a lack of consensus with regard to a definition for acute renal
failure. This is exemplified by the need to change the criteria
for entry into this study after 8 months due to the inclusion
rate being too low.
So what conclusions can be drawn from this study?
Vinsonneau and colleagues fail to demonstrate any differen-
ces in 60-day mortality between the two groups and con-
clude that all patients with acute renal failure as part of
multiple-organ dysfunction syndrome can be treated with
intermittent haemodialysis [7]. But can these conclusions
really be drawn? A problem when comparing any two
treatments is ensuring both adequate and comparative
dosing regimens, and herein lies a major flaw in this study.
The study started more than 7 years ago, during which time
the practices in both continuous venovenous
haemodiafiltration and IHD have changed considerably [8,9].
As conceded by Vinsonneau and colleagues, this may have
lead to changes in investigator practices during the study
period, particularly with respect to the delivered dose of renal
support. This possibility, however, is hard to ascertain given
that the dialysis dose in the IHD group is not stated.
Interestingly the mortality decreased in the IHD arm of the
study over the time of recruitment, which reflected a change
in practice towards an increase in dialysis prescription. Given
the lack of control regarding the dosage in both arms of the
study, definitive conclusions are hard to make regarding
treatment. Furthermore, doubts exist regarding the statistical
power of the study – a point raised in the excellent
accompanying clinical comment, which concludes that whether
IHD is as good as or even better than continuous renal
replacement therapy cannot be answered by this study [10].
The debate surrounding the use of albumin in the critically ill
will continue to run until a well-designed, adequately powered
study to definitively answer this question is undertaken. This
study would need strict adherence to the delivered dose,
would need to assess the timing of initiation of treatment
(perhaps employing the Risk, Injury, Failure, Loss and End-
stage Kidney Classification: RIFLE criteria) and should examine
more secondary endpoints. So what is the answer? Perhaps
the best practice is to offer the patient the technique with
which the unit is most familiar until we have a definitive answer.
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